Adial Pharmaceuticals Inc
$ 2.13
-3.62%
09 Jun - close price
- Market Cap 4,565,900 USD
- Current Price $ 2.13
- High / Low $ 2.22 / 2.12
- Stock P/E N/A
- Book Value 2.46
- EPS -4.89
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -1.11 %
- ROE -2.66 %
- 52 Week High 18.90
- 52 Week Low 1.31
About
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapies for the treatment or prevention of addictions and related disorders. The company is headquartered in Charlottesville, Virginia.
Analyst Target Price
$25.00
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-08 | 2026-03-10 | 2025-11-13 | 2025-08-13 | 2025-05-14 | 2025-03-04 | 2024-11-13 | 2024-08-13 | 2024-04-04 | 2024-02-20 | 2023-11-14 | 2023-08-21 |
| Reported EPS | -1.48 | -11.48 | -0.08 | -0.18 | -0.34 | -0.15 | -0.38 | -0.59 | -0.62 | -1.35 | -1.18 | 0.96 |
| Estimated EPS | -2.25 | -2.13 | -0.39 | -0.39 | -0.495 | -0.33 | -0.44 | -0.53 | -0.33 | -0.76 | -1.13 | -1.5 |
| Surprise | 0.77 | -9.35 | 0.31 | 0.21 | 0.155 | 0.18 | 0.06 | -0.06 | -0.29 | -0.59 | -0.05 | 2.46 |
| Surprise Percentage | 34.2222% | -438.9671% | 79.4872% | 53.8462% | 31.3131% | 54.5455% | 13.6364% | -11.3208% | -87.8788% | -77.6316% | -4.4248% | 164% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: ADIL
2026-06-09 19:09:29
This article provides details on Adial Pharmaceuticals (ADIL) stock options chain, along with related quotes and news.
2026-06-09 18:09:29
This page provides access to Adial Pharmaceuticals, Inc.'s SEC filings and other financial documents, including Forms 10-K, 10-Q, and 8-K. It details past earnings reports and corporate events, highlighting key developments such as advancements in their AD04 drug for AUD, financial performance, and regulatory milestones. The information is designed to help users evaluate the company's financial and operational status.
2026-05-19 17:08:44
This article lists several healthcare stocks experiencing significant price movements during Tuesday's intraday trading session. Gainers include InMed Pharmaceuticals, MetaVia, Co-Diagnostics, Edesa Biotech, and Adial Pharmaceuticals, with increases ranging from 29.5% to 127%. Losers include WORK Medical Tech Gr, Autonomix Medical, AIM ImmunoTech, Akanda, Psyence Biomedical, and Quantum Cyber, with declines from 16.67% to 39%.
2026-05-15 15:10:04
Armistice Capital, LLC and Steven Boyd have reported a beneficial ownership of 274,139 shares of Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) common stock, representing 4.99% of the class. This disclosure, filed as a SCHEDULE 13G/A, indicates that Armistice Capital exercises shared voting and dispositive power over these shares through an Investment Management Agreement. The filing emphasizes manager-level control rather than direct sole control, with the Master Fund being the direct holder of the shares.
2026-05-11 23:09:40
Adial Pharmaceuticals reported a Q1 net income of USD -2 million. This brief financial update was provided by Refinitiv and indicates the company's financial performance for the first quarter.
2026-05-11 23:09:39
Adial Pharmaceuticals reported its Q1 2026 financial results, highlighting progress on AD04 for Alcohol Use Disorder. The company noted favorable FDA policy shifts that could reduce development costs and emphasized growing support for patient-centered clinical trial endpoints. Adial also announced a collaboration framework with Molteni Farmaceutici for AD04 in Europe and strengthened its intellectual property with a patent application expected to provide protection until 2045.
